Loprox

Manufacturer
Bausch Health US, LLC | Contract Pharmaceuticals Limited Canada | Bausch Health Companies Inc.
Effective date
2019-05-01
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
16
Source
legacy-cache
Hydrated at
2026-08-01 22:49:44

Label at a glance#

ProductLoprox
Active ingredientciclopirox
Label structure15 sections

Indications and uses

LOPROX ® (ciclopirox) Shampoo, 1% is indicated for the topical treatment of seborrheic dermatitis of the scalp in adults.

Dosage and administration

LOPROX Shampoo is not for ophthalmic, oral, or intravaginal use. Wet hair and apply approximately 1 teaspoon (5 mL) of LOPROX Shampoo to the scalp. Up to 2 teaspoons (10 mL) may be used for long hair. Lather and leave on hair and scalp for 3 minutes. A timer may be used. Avoid contact with eyes. Rinse off. Treatment should be repeated twice per week for 4 weeks, with a minimum of 3 days between applications. If a ...

Storage and handling

LOPROX (ciclopirox) Shampoo, 1% is colorless and translucent, and supplied in 120 mL plastic bottles (NDC 99207-010-10). Discard unused product after initial treatment duration. Store between 15° to 30°C (59° to 86°F). Keep out of reach of children.

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

LOPROX® (ciclopirox) Shampoo, 1% is indicated for the topical treatment of seborrheic dermatitis of the scalp in adults.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

LOPROX Shampoo is not for ophthalmic, oral, or intravaginal use.

Wet hair and apply approximately 1 teaspoon (5 mL) of LOPROX Shampoo to the scalp. Up to 2 teaspoons (10 mL) may be used for long hair. Lather and leave on hair and scalp for 3 minutes. A timer may be used. Avoid contact with eyes. Rinse off. Treatment should be repeated twice per week for 4 weeks, with a minimum of 3 days between applications.

If a patient with seborrheic dermatitis shows no clinical improvement after 4 weeks of treatment with LOPROX Shampoo, the diagnosis should be reviewed.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

LOPROX is a shampoo containing 1% ciclopirox.

Each gram (equivalent to 0.96 mL) of LOPROX Shampoo contains 10 mg ciclopirox in a colorless and translucent shampoo base.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

None.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Local Effects

SPL UNCLASSIFIED SECTION

If a reaction suggesting sensitivity or irritation occurs with the use of LOPROX Shampoo, treatment should be discontinued and appropriate therapy instituted.

Contact of LOPROX Shampoo with the eyes should be avoided. If contact occurs, rinse thoroughly with water.

In patients with lighter hair color, hair discoloration has been reported.

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

6.1 Clinical Trials Experience

SPL UNCLASSIFIED SECTION

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In 626 subjects treated with LOPROX Shampoo twice weekly in the two pivotal clinical trials, the most frequent adverse events were increased itching in 1% of subjects, and application site reactions, such as burning, erythema, and itching, also in 1% of subjects.

6.2 Postmarketing Experience

SPL UNCLASSIFIED SECTION

The following adverse reactions have been identified during post-approval use of LOPROX Shampoo: hair discoloration and abnormal hair texture, alopecia, irritation, and rash. Because these events are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

TERATOGENIC EFFECTS SECTION

Teratogenic Effects: Pregnancy Category B

There are no adequate or well-controlled studies in pregnant women. Therefore, LOPROX Shampoo should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Oral embryofetal developmental studies were conducted in mice, rats, rabbits, and monkeys. Ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80, and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits, and monkeys, respectively (approximately 13, 42, 54, and 26 times the maximum recommended human dose based on body surface area comparisons, respectively).

Dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in PEG 400. Ciclopirox olamine was topically administered during the period of organogenesis. No maternal toxicity, embryotoxicity, or teratogenicity were noted at the highest doses of 92 mg/kg/day and 77 mg/kg/day ciclopirox in rats and rabbits, respectively (approximately 31 and 54 times the maximum recommended human dose based on body surface area comparisons, respectively).

8.3 Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when LOPROX Shampoo is administered to a nursing woman.

8.4 Pediatric Use

PEDIATRIC USE SECTION

No clinical trials have been conducted in subjects younger than 16 years.

8.5 Geriatric Use

GERIATRIC USE SECTION

In clinical trials, the safety and tolerability of LOPROX Shampoo in the population 65 years and older was comparable to that of younger subjects. Results of the efficacy analysis in those subjects 65 years and older showed effectiveness in 25 of 85 (29%) subjects treated with LOPROX Shampoo, and in 15 of 61 (25%) subjects treated with the vehicle; due to the small sample size, a statistically significant difference was not demonstrated. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity to adverse effects in some older individuals cannot be ruled out.

11 DESCRIPTION

DESCRIPTION SECTION

LOPROX (ciclopirox) Shampoo, 1% contains the synthetic antifungal agent ciclopirox for topical use.

Each gram (equivalent to 0.96 mL) of LOPROX Shampoo contains 10 mg ciclopirox in a shampoo base consisting of disodium laureth sulfosuccinate, laureth-2, purified water, sodium chloride, and sodium laureth sulfate.

LOPROX Shampoo is a colorless, translucent solution. The chemical name for ciclopirox is 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, with the empirical formula C12H17NO2 and a molecular weight of 207.27. The CAS Registry Number is [29342-05-0]. The chemical structure is:

loprox-01.jpg
loprox-01.jpg

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

Ciclopirox is a hydroxypyridone antifungal agent although the relevance of this property for the indication of seborrheic dermatitis is not known. Ciclopirox acts by chelation of polyvalent cations (Fe3+ or Al3+), resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell.

12.2 Pharmacodynamics

PHARMACODYNAMICS SECTION

The pharmacodynamics of LOPROX Shampoo are unknown.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

In a study in patients with seborrheic dermatitis of the scalp, application of 5 mL ciclopirox shampoo, 1% twice weekly for 4 weeks, with an exposure time of 3 minutes per application, resulted in detectable serum concentrations of ciclopirox in 6 out of 18 patients. The serum concentrations measured throughout the dosing interval on Days 1 and 29 ranged from 10.3 ng/mL to 13.2 ng/mL. Total urinary excretion of ciclopirox was less than 0.5% of the administered dose.

12.4 Microbiology

MICROBIOLOGY SECTION

Ciclopirox is fungicidal in vitro against Malassezia furfur (Pityrosporum spp.), P. ovale, and P. orbiculare.

The clinical significance of antifungal activity in the treatment of seborrheic dermatitis is not known.

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

A 104-week dermal carcinogenicity study in mice was conducted with ciclopirox cream applied at doses up to 1.93% (100 mg/kg/day or 300 mg/m2/day). No increase in drug-related neoplasms was noted when compared to control.

The following in vitro genotoxicity tests have been conducted with ciclopirox: evaluation of gene mutation in the Ames Salmonella and E. coli assays (negative); chromosome aberration assays in V79 Chinese hamster lung fibroblast cells, with and without metabolic activation (positive); chromosome aberration assays in V79 Chinese hamster lung fibroblast cells in the presence of supplemental Fe3+, with and without metabolic activation (negative); gene mutation assays in the HGPRT-test with V79 Chinese hamster lung fibroblast cells (negative); and a primary DNA damage assay (i.e., unscheduled DNA synthesis assay in A549 human cells) (negative). An in vitro cell transformation assay in BALB/c 3T3 cells was negative for cell transformation. In an in vivo Chinese hamster bone marrow cytogenetic assay, ciclopirox was negative for chromosome aberrations at a dosage of 5,000 mg/kg body weight.

A combined oral fertility and embryofetal developmental study was conducted in rats with ciclopirox olamine. No effect on fertility or reproductive performance was noted at the highest dose tested of 3.85 mg/kg/day ciclopirox (approximately 1.3 times the maximum recommended human dose based on body surface area comparisons).

14 CLINICAL STUDIES

CLINICAL STUDIES SECTION

In two randomized, double-blind clinical trials, subjects 16 years and older with seborrheic dermatitis of the scalp applied LOPROX Shampoo or its vehicle twice weekly for 4 weeks. Subjects who were immunocompromised, those with psoriasis or atopic dermatitis, women of childbearing potential not using adequate contraception, and pregnant or lactating women were excluded from the clinical trials. An evaluation of the overall status of the seborrheic dermatitis, the presence and severity of erythema or inflammation, and scaling was made at Week 4, using a scale of 0=none, 1=slight, 2=mild, 3=moderate, 4=pronounced, and 5=severe. Effective treatment was defined as achieving a score of 0 (or a score of 1 if the baseline score was ≥3) simultaneously for status of the seborrheic dermatitis, erythema or inflammation, and scaling at Week 4. Ciclopirox shampoo was shown to be statistically significantly more effective than vehicle in both trials. Efficacy results for the two trials are presented in Table 1 below.

Table 1. Effective Treatment Rates at Week 4 in Trials 1 and 2
Ciclopirox
Shampoo
Vehicle

Study 1

220/380 (58%)

60/192 (31%)

Study 2

65/250 (26%)

32/249 (13%)

Efficacy for African American subjects was not demonstrated, although only 53 African American subjects were enrolled in the two pivotal trials.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

LOPROX (ciclopirox) Shampoo, 1% is colorless and translucent, and supplied in 120 mL plastic bottles
(NDC 99207-010-10).

Discard unused product after initial treatment duration.

STORAGE AND HANDLING SECTION

Store between 15° to 30°C (59° to 86°F).

Keep out of reach of children.

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

The patient should be instructed to:

  • Use LOPROX Shampoo as directed by the physician. Avoid contact with the eyes. If contact occurs, rinse thoroughly with water. LOPROX Shampoo is for external use on the scalp only. Do not swallow.
  • Use LOPROX Shampoo for seborrheic dermatitis for the full treatment time even though symptoms may have improved. Notify the physician if there is no improvement after 4 weeks.
  • Inform the physician if the area of application shows signs of increased irritation (redness, itching, burning, blistering, swelling, or oozing).

Manufactured for:
Bausch Health US, LLC
Bridgewater, NJ 08807 USA

Manufactured by:
Bausch Health Companies Inc.
Laval, Quebec H7L 4A8, Canada

LOPROX is a trademark of Bausch Health Companies Inc. or its affiliates.

© 2019 Bausch Health Companies Inc. or its affiliates

9505303

SPL PATIENT PACKAGE INSERT SECTION

Patient Information
LOPROX® (loh-proks)
(ciclopirox)
Shampoo

Important: For use on the scalp only. Do not get LOPROX Shampoo in your eyes, mouth, or vagina.

What is LOPROX Shampoo?

LOPROX Shampoo is a prescription medicine used on the scalp to treat adults with a skin condition called seborrheic dermatitis.

It is not known if LOPROX Shampoo is safe and effective in children under 16 years of age.

What should I tell my doctor before using LOPROX Shampoo?

Before using LOPROX Shampoo, tell your doctor if you:

  • have any other medical conditions.
  • are pregnant or plan to become pregnant. It is not known if LOPROX Shampoo will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if LOPROX Shampoo passes into your breast milk.
  • are taking prescription and nonprescription medicines, vitamins, and herbal supplements.

    Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

How should I use LOPROX Shampoo?

  • Use LOPROX Shampoo exactly as your doctor tells you to use it.
  • Wash your hair using LOPROX Shampoo 2 times each week for 4 weeks. There should be at least 3 days between each time you use LOPROX Shampoo.
  • Use LOPROX Shampoo for 4 weeks even if your skin condition improves.
  • Tell your doctor if your scalp condition is not getting better after you have used LOPROX Shampoo for 4 weeks.
  • Do not swallow LOPROX Shampoo.
  • Avoid getting LOPROX Shampoo in your eyes. If LOPROX Shampoo gets into your eyes, rinse them well with water.

How should I apply LOPROX Shampoo?

  • Wet your hair and apply approximately 1 teaspoon of LOPROX Shampoo to your scalp. You may use up to 2 teaspoons of LOPROX Shampoo if you have long hair. Lather and leave LOPROX Shampoo on your hair and scalp for 3 minutes. You may use a timer.
  • After 3 minutes have passed, rinse your hair and scalp.

What are the possible side effects of LOPROX Shampoo?

The most common side effects of LOPROX Shampoo include: itching, burning, and redness of the scalp. Tell your doctor if you get any of these symptoms and they become worse or do not go away, or if you get blistering, swelling, or oozing in your scalp.

These are not all the possible side effects of LOPROX Shampoo. For more information, ask your doctor.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store LOPROX Shampoo?

  • Store LOPROX Shampoo at room temperature, between 59° to 86°F (15° to 30°C).
  • Safely throw away any unused LOPROX Shampoo after you finish your treatment.

Keep LOPROX Shampoo and all medicines out of reach of children.

General information about LOPROX Shampoo

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use LOPROX Shampoo for a condition for which it was not prescribed. Do not give LOPROX Shampoo to other people, even if they have the same symptoms you have. It may harm them.

You can ask your pharmacist or doctor for information about LOPROX Shampoo that is written for health professionals.

For more information about LOPROX Shampoo, call 1-800-321-4576.

What are the ingredients in LOPROX Shampoo?

Active ingredient: ciclopirox

Inactive ingredients: disodium laureth sulfosuccinate, laureth-2, purified water, sodium chloride, and sodium laureth sulfate.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Manufactured for:
Bausch Health US, LLC
Bridgewater, NJ 08807 USA

Manufactured by:
Bausch Health Companies Inc.
Laval, Quebec H7L 4A8, Canada

LOPROX is a trademark of Bausch Health Companies Inc. or its affiliates.

© 2019 Bausch Health Companies Inc. or its affiliates

9505303

Rev. 05/2019

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL



PRINCIPAL DISPLAY PANEL - 120 mL Bottle Carton

NDC 99207-010-10

Rx only

LOPROX®
SHAMPOO
(ciclopirox) 1%

FOR TOPICAL USE ONLY
NOT FOR OPHTHALMIC, ORAL OR INTRAVAGINAL USE
KEEP OUT OF REACH OF CHILDREN

120 mL

Ortho Dermatologics

carton.jpg
carton.jpg

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
99207-010-10ML - Milliliter99207-0106ebe6777-1c8f-4eb6-ba43-96750a89374912012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
ciclopiroxACTIVE INGREDIENT19W019ZDRJ8
ciclopiroxACTIVE MOIETY19W019ZDRJ8
disodium laureth sulfosuccinateINACTIVE INGREDIENTD6DH1DTN7E8
laureth-2INACTIVE INGREDIENTD4D38LT1L58
sodium chlorideINACTIVE INGREDIENT451W47IQ8X8
sodium laureth-3 sulfateINACTIVE INGREDIENTBPV390UAP08
waterINACTIVE INGREDIENT059QF0KO0R8

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 7 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
99207-01099207-010-10, 99207-010-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Source Document#

Source XML · Source PDF

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 3 · 142 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / INTRADERMAL7 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, POWDER, FOR SOLUTION / INTRAVENOUS2922 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION / AURICULAR (OTIC)0.9 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SUSPENSION / INTRAVITREAL6 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSPRAY, METERED / NASAL36 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION / INTRAMUSCULAR9 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INFILTRATION3535 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XTABLET / ORAL231 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XTABLET, COATED / ORAL54.7 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XIMPLANT / SUBCUTANEOUS77 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION / SUBCUTANEOUS90 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / SUBMUCOSAL17 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION / NASAL330 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium laureth-3 sulfateSODIUM LAURETH-3 SULFATEBPV390UAP0SPRAY / TOPICAL0.1 %w/wExact identifier — unii candidate
5 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR226 mgExact identifier — unii candidate
134 equally ranked IID candidates
laureth-2LAURETH-2D4D38LT1L5SHAMPOO / TOPICAL2 %w/wExact identifier — unii candidate
sodium chlorideSODIUM CHLORIDE451W47IQ8XSUPPOSITORY / RECTAL140 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION, CONCENTRATE / INTRAMUSCULAR0.86 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / INTRAVASCULAR0.86 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / INTRA-ARTICULAR26 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XGEL / OPHTHALMIC0.9 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION / INTRAPERITONEAL0.54 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XLIQUID / INTRAVENOUS6320 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION / RECTALNAExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / EPIDURAL648 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION/ DROPS / TOPICAL0.86 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION / ENDOTRACHEAL7.6 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION/ DROPS / AURICULAR (OTIC)3 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION / ORAL1126 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRA-ARTERIAL278 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XENEMA / RECTAL0.7 %w/wExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XGRANULE, FOR SUSPENSION / ORAL162 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION/ DROPS / OPHTHALMIC3 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XPOWDER / RESPIRATORY (INHALATION)NAExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAVESICAL351 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XPOWDER, FOR SUSPENSION / ENDOTRACHEAL46.76 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSYSTEM / TOPICAL3.1 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION / INTRAVENOUS90 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION/ DROPS / AURICULAR (OTIC)18 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOAP / TOPICAL1.26 %w/wExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, EMULSION / INTRAVENOUS0.62 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / DENTAL0.4 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SUSPENSION, LIPOSOMAL / EPIDURAL11 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XCAPSULE, EXTENDED RELEASE / ORAL41 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / INFILTRATION648 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION / TOPICAL0.32 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / SUBCUTANEOUS1486 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION, CONCENTRATE / SUBCUTANEOUS0.86 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XTABLET, DELAYED RELEASE / ORAL97 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSYRUP / ORAL40 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SUSPENSION / INTRASYNOVIAL4 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XPOWDER, FOR SUSPENSION / ORAL98 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XTABLET, CHEWABLE / ORAL20 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION, CONCENTRATE / INTRAVENOUS0.86 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
disodium laureth sulfosuccinateDISODIUM LAURETH SULFOSUCCINATED6DH1DTN7ESHAMPOO / TOPICAL1530 mgExact identifier — unii candidate
2 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSPRAY / NASAL30 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / INTRAMUSCULAR1486 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / EPIDURAL3535 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION / RESPIRATORY (INHALATION)43 mgExact identifier — unii candidate
134 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N021159-001LOPROXCICLOPIROX1%SHAMPOO / TOPICALRLD2003-02-28

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09N021159-001LOPROX1%SHAMPOO / TOPICALRLD2003-02-28c2088c7a36db…
2026-09-14 22:38:342026-08N021159-001LOPROX1%SHAMPOO / TOPICALRLD2003-02-2884e616aacf4f…
2026-08-18 06:07:402026-07N021159-001LOPROX1%SHAMPOO / TOPICALRLD2003-02-28caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N021159-001LOPROX1%SHAMPOO / TOPICALRLD2003-02-28011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N021159-001LOPROX1%SHAMPOO / TOPICALRLD2003-02-2831067a03dcf5…
2025-08-23 18:47 UTC2025-08N021159-001LOPROX1%SHAMPOO / TOPICALRLD2003-02-286a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-28fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-28b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-2803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-282680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-285bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-28d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-28d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-2879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-28301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-281e350fbaab3a…
2024-05-31 18:47 UTC2024-05N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-288072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-285c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-285d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-284b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-2874a2ff9319b5…
2022-03-09 01:35 UTC2022-03N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-28bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-28782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-2887673890dc5c…
2021-03-12 10:30 UTC2021-03N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-285aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-288869cabd3fbd…
2020-11-12 02:37 UTC2020-11N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-28c0c555d07b60…
2019-12-14 00:12 UTC2019-12N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-283f01610625f2…
2019-09-15 20:21 UTC2019-09N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-28b00525d2431f…
2019-07-19 19:46 UTC2019-07N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-28ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-286a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-281c564ffb4f44…
2023-12-20 04:57 UTC2023-12N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-28ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-28a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-289b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-28a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-283f0d92c62455…
2023-05-13 08:27 UTC2023-05N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-28053a50430f4f…
2023-01-26 05:58 UTC2023-01N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-283bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N021159-001LOPROX1%SHAMPOO / TOPICALATRLD, RS2003-02-283a93d1ddd44b…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N021159-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N021159-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N021159-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N021159-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N021159-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N021159-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N021159-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N021159-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N021159-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N021159-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N021159-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N021159-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N021159-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N021159-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N021159-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03N021159-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N021159-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N021159-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03N021159-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N021159-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11N021159-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12N021159-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09N021159-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07N021159-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N021159-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N021159-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12N021159-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N021159-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N021159-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N021159-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N021159-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05N021159-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01N021159-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N021159-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N021159-001AT1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09N021159-001AT1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07N021159-001AT1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
29a2397f-f17a-ec70-e063-6394a90a0a7f464a1be3-b72b-424d-b11b-a8f26126cce72024-12-19Warnings, Adverse reactionsExact identifier
spl set id: 464a1be3-b72b-424d-b11b-a8f26126cce7

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.